David J. Berry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David J. Berry has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan William Steed
Department of Chemistry, Durham University, South Road, Durham, DH1 3LE, UK
5 shared publications - Melissa J. Goodwin
University of Twente
3 shared publications Dmitry S. Yufit
Department of Chemistry, Lower Mountjoy, Durham University, Stockton Road, Durham, DH1 3LE, U.K.
2 shared publicationsJ. Jonathan Harburn
School of Medicine, Pharmacy and Health, Durham University , Queen's Campus, Stockton on Tees, TS17 6BH, U.K.
2 shared publicationsOsama M. Musa
Ashland LLC, 1005 Route 202/206, Bridgewater, New Jersey 08807, United States
2 shared publicationsAndrea Perrin
Department of Chemistry, Durham University, Lower Mountjoy, Stockton Road, Durham, DH1 3LE, U.K.
1 shared publication
Latest Publications
- 8 January 2018
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 18 (2) , 701-709
Small-Molecule Povidone Analogues in Coamorphous Pharmaceutical Phases
- 8 January 2018
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 18 (2) , 701-709
Small-Molecule Povidone Analogues in Coamorphous Pharmaceutical Phases
- 25 September 2017
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 17 (10) , 5552-5558
Halogen and Hydrogen Bonding in Povidone-Iodine and Related Co-Phases
- 25 September 2017
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 17 (10) , 5552-5558
Halogen and Hydrogen Bonding in Povidone-Iodine and Related Co-Phases
- Top Cited PapersOpen Access
- 1 August 2017
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 117, 3-24
Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design
- 1 August 2017
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 117, 3-24
Top Cited PapersOpen AccessPharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design
- 10 May 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (10) , 4496-4502
Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs
Matrix metalloproteinases (MMPs) are central to cancer development and metastasis. They are highly active in the tumor environment and absent or inactive in normal tissues; therefore they represent viable targets for cancer drug discovery. In this study we evaluated in silico docking to develop MMP-subtype-selective tumor-activated prodrugs. Proof of principle for this therapeutic approach was demonstrated in vitro against an aggressive human glioma model, with involvement of MMPs confirmed using pharmacological inhibition.
- 10 May 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (10) , 4496-4502
Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs
Matrix metalloproteinases (MMPs) are central to cancer development and metastasis. They are highly active in the tumor environment and absent or inactive in normal tissues; therefore they represent viable targets for cancer drug discovery. In this study we evaluated in silico docking to develop MMP-subtype-selective tumor-activated prodrugs. Proof of principle for this therapeutic approach was demonstrated in vitro against an aggressive human glioma model, with involvement of MMPs confirmed using pharmacological inhibition.
- 26 April 2017
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 17 (6) , 3236-3249
Hydration Behavior of Polylactam Clathrate Hydrate Inhibitors and Their Small-Molecule Model Compounds
- 26 April 2017
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 17 (6) , 3236-3249
Hydration Behavior of Polylactam Clathrate Hydrate Inhibitors and Their Small-Molecule Model Compounds
- Open Access
- 18 April 2016
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 52 (39) , 6537-6540
Stabilisation of an amorphous form of ROY through a predicted co-former interaction
The highly polymorphic compound ROY was the subject of a co-crystal screen. No co-crystals were found, but the study highlights the potential for future prediction of co-amorphous behaviours by determining an interaction between ROY and pyrogallol.
- 18 April 2016
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 52 (39) , 6537-6540
Open AccessStabilisation of an amorphous form of ROY through a predicted co-former interaction
The highly polymorphic compound ROY was the subject of a co-crystal screen. No co-crystals were found, but the study highlights the potential for future prediction of co-amorphous behaviours by determining an interaction between ROY and pyrogallol.
- Open Access
- 15 March 2016
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 18 (15) , 2617-2620
Tuning the spontaneous formation kinetics of caffeine : malonic acid co-crystals
It has previously been reported that the caffeine : malonic acid co-crystal system forms spontaneously upon the contact of the two materials, here we explore the mechanism of this formation and control the kinetics to enable us to monitor the conversion.
- 15 March 2016
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 18 (15) , 2617-2620
Open AccessTuning the spontaneous formation kinetics of caffeine : malonic acid co-crystals
It has previously been reported that the caffeine : malonic acid co-crystal system forms spontaneously upon the contact of the two materials, here we explore the mechanism of this formation and control the kinetics to enable us to monitor the conversion.
- 11 March 2014
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 16 (26) , 5753-5761
Pharmaceutical co-crystals – are we there yet?
In the pharmaceutical arena it is agreed that co-crystals form a vital part of the solid-state toolbox, allowing the progression of novel compounds through the development pathway to patients and improving properties in older medicines. Sadly though, few co-crystals have made it to the market in the form of a new licensed product. This displays a disconnect between research effort and end product. For some time now it has been possible to determine the formation of co-crystals, by a variety of screening and analytical means; although it is recognised that there will always be phases that sit in the ‘greyer’ area of the salt-co-crystal continuum. It is also possible, with limitations, to predict the formation of co-crystals in silico via energetic and structural considerations. So what are the major hurdles and missing links, and what are the key structural properties we need to study to improve the success rate? This highlight hopes to address these.
- 11 March 2014
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 16 (26) , 5753-5761
Pharmaceutical co-crystals – are we there yet?
In the pharmaceutical arena it is agreed that co-crystals form a vital part of the solid-state toolbox, allowing the progression of novel compounds through the development pathway to patients and improving properties in older medicines. Sadly though, few co-crystals have made it to the market in the form of a new licensed product. This displays a disconnect between research effort and end product. For some time now it has been possible to determine the formation of co-crystals, by a variety of screening and analytical means; although it is recognised that there will always be phases that sit in the ‘greyer’ area of the salt-co-crystal continuum. It is also possible, with limitations, to predict the formation of co-crystals in silico via energetic and structural considerations. So what are the major hurdles and missing links, and what are the key structural properties we need to study to improve the success rate? This highlight hopes to address these.